Adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy extended OS among a subset of older adults with newly diagnosed acute myeloid leukemia, according to results of the phase 3 QuANTUM-First trial.
The findings, presented during the European Hematology Association Hybrid 2022 Congress, additionally showed quizartinib (Daiichi Sankyo) had a favorable safety profile, suggesting the agent is safe and effective for patients aged up to 75 years with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) acute myeloid leukemia.
“The prognosis of